Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Meningeal Neoplasms 1Medulloblastoma 1Hepatoblastoma 1

Interventions

3-Iodobenzylguanidine 9Cyclophosphamide 6Amifampridine 6nilotinib 5fludarabine 5Magnetic Resonance Spectroscopy 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine phosphate 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × omburtamab I-131 × Clear all
NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Memorial Sloan Kettering Cancer Center

No longer available
CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡